ImmunityBio Inc (IBRX)
7.01
-0.74
(-9.55%)
USD |
NASDAQ |
May 20, 11:44
ImmunityBio Net Income (Quarterly): -134.11M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -134.11M |
| December 31, 2023 | -233.39M |
| September 30, 2023 | -95.58M |
| June 30, 2023 | -137.88M |
| March 31, 2023 | -116.34M |
| December 31, 2022 | -108.22M |
| September 30, 2022 | -110.94M |
| June 30, 2022 | -94.59M |
| March 31, 2022 | -102.83M |
| Date | Value |
|---|---|
| December 31, 2021 | -91.26M |
| September 30, 2021 | -87.63M |
| June 30, 2021 | -88.29M |
| March 31, 2021 | -79.61M |
| December 31, 2020 | -67.77M |
| September 30, 2020 | -65.60M |
| June 30, 2020 | -51.44M |
| March 31, 2020 | -37.04M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-233.39M
Minimum
Dec 2023
-37.04M
Maximum
Mar 2020
-100.15M
Average
-94.59M
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | -4.146M |
| iBio Inc | -8.211M |
| Lixte Biotechnology Holdings Inc | -0.9713M |
| Abeona Therapeutics Inc | -31.58M |
| Chromocell Therapeutics Corp | -1.422M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.04M |
| Total Expenses (Quarterly) | 95.24M |
| EPS Diluted (Quarterly) | -0.20 |
| Enterprise Value | 5.808B |
| Profit Margin (Quarterly) | -335.3K% |
| Earnings Yield | -15.55% |
| Normalized Earnings Yield | -13.79 |